$52.85
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Enliven Therapeutics Insider Sold Shares Worth $263,373, According to a Recent SEC Filing
Enliven Therapeutics Insider Sold Shares Worth $316,780, According to a Recent SEC Filing
Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing
Overview
52-week range
$15
$49
100% of range
Avg surprise (last 3)
+3.1%
Avg reaction (last 2)
-1.5%
0% positive
Latest IV / EM
65%
EM ±14.9% · $55 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.38 | $-0.44 | +13.6% | +33.3% | -2.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.32 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.49 | $-0.53 | +7.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.57 | $-0.51 | -11.8% | — | -0.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.48 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.41 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.54 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.51 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.41 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.38 | -$0.49 | +22.4% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-28M | — | $-25M | $-29M | $-32M | — | $-27M | $-25M |
| Net income | $-24M | — | $-20M | $-25M | $-29M | — | $-23M | $-20M |
| EPS (diluted) | $-0.38 | — | $-0.32 | $-0.49 | $-0.57 | — | $-0.48 | $-0.41 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $132M | $99M | $102M | $119M | $102M | $124M | $101M | $97M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $463M | $475M | $483M | $496M | $294M | $318M | $297M | $318M |
| Total assets | $465M | $476M | $491M | $504M | $303M | $326M | $305M | $327M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $11M | $17M | $15M | $15M | $14M | $16M | $17M | $22M |
| Total equity | $453M | $460M | $476M | $488M | $288M | $310M | $288M | $305M |